Episodios

  • New Retina Radio Journal Club w/ VBS: Assessing Surgical Competency Among Retina Fellows: Perspectives from Directors and Graduates

    New Retina Radio Journal Club w/ VBS: Assessing Surgical Competency Among Retina Fellows: Perspectives from Directors and Graduates
    Dec 18 2025
    How do we know when a retina fellow is truly ready for independent surgery? Nikisha Kothari, MD, moderates a discussion with Jesse Sengillo, MD, and Nicholas Farber, MD, about a new survey study comparing perspectives from fellowship program directors and recent graduates on surgical volumes, teaching tools, autonomy, and competency benchmarks. The group explores areas of agreement, gaps in current training, and the push for more systematic assessment models in retina training.
    Más Menos
    21 m
  • DME, DR, and Next-Generation Therapies

    DME, DR, and Next-Generation Therapies
    Dec 9 2025
    How should retina specialists integrate next-generation anti-VEGF agents into real-world DME care? In this episode of “Anti-VEGFs: The Next Generation,” David Miller, MD, speaks with Esther Kim, MD, and Ehsan Rahimy, MD, about first-line agent selection, when to transition to newer options, how to incorporate steroids thoughtfully, and crafting dosing strategies that balance durability, efficacy, and adherence for working-age patients—without overpromising outcomes.This editorially independent series is supported with advertising by Regeneron.
    Más Menos
    17 m
  • Wet AMD and Next-Generation Therapies

    Wet AMD and Next-Generation Therapies
    Dec 9 2025
    How should retina specialists integrate next-generation anti-VEGFs into everyday wet AMD care? In this episode of “Anti-VEGFs: The Next Generation,” David Miller, MD, speaks with Esther Kim, MD, and Ehsan Rahimy, MD, about real-world issues facing wet AMD care, such as navigating crowded drug fridges, attempting interval extensions, and switching from legacy agents to next-generations treatments. This editorially independent series is supported with advertising by Regeneron.
    Más Menos
    18 m
  • Retinal Fluid Fluctuation’s Impact on Long-Term Visual Acuity (Ep. 3 of 3)

    Retinal Fluid Fluctuation’s Impact on Long-Term Visual Acuity (Ep. 3 of 3)
    Dec 4 2025
    Can smarter strategies to tame retinal fluid fluctuations actually improve long-term vision? In episode 3 of this miniseries, host Jay Sridhar, MD, and panelists Durga Borkar, MD, MMCi, and Christina Weng, MD, MBA, examine the data linking sustained delivery of therapy, reductions in retinal thickness changes, and positive long-term vision outcomes. After the break, the trio looks ahead to sustained TKI therapy via EYP-1901 (Duravyu, EyePoint Pharmaceuticals) by examining data from the DAVIO-2 study. Drs. Sridhar, Borkar, and Weng are paid consultants of EyePoint Pharmaceuticals; however, the statements made are the opinions of Drs. Sridhar, Borkar, and Weng for educational purposes only; their statements are not intended as medical advice or the opinion of EyePoint.
    Más Menos
    29 m
  • Retinal Fluid Fluctuation’s Impact on Long-Term Visual Acuity (Ep. 2 of 3)

    Retinal Fluid Fluctuation’s Impact on Long-Term Visual Acuity (Ep. 2 of 3)
    Dec 4 2025
    Do retinal fluid fluctuations quietly erode long-term vision? In episode 2 of a 3-part roundtable series, moderator Jay Sridhar, MD joins guests Maggie Runner, MD, and Veeral Sheth, MD, MBA, to translate key data into clinic-ready tactics. They unpack how volatility—not just volume—of fluid correlates with outcomes, which fluid compartments matter most, and why durability reduces “yo-yo” anatomy. Drs. Sridhar, Runner, and Sheth are paid consultants of EyePoint Pharmaceuticals; however, the statements made are the opinions of Drs. Sridhar, Runner, and Sheth for educational purposes only; their statements are not intended as medical advice or the opinion of EyePoint.
    Más Menos
    27 m
  • Retinal Fluid Fluctuation’s Impact on Long-Term Visual Acuity (Ep. 1 of 3)

    Retinal Fluid Fluctuation’s Impact on Long-Term Visual Acuity (Ep. 1 of 3)
    Dec 4 2025
    In this first episode of a 3-part roundtable series, moderator Jay Sridhar, MD, speaks with David Sarraf, MD, and Danny Mammo, MD, about retinal fluid fluctuation as a modifiable driver of outcomes in neovascular AMD and DME. The panel defines fluctuation across compartments, examines practical barriers to longitudinal OCT tracking, and assesses the undertreatment gap in real-world practice. Drs. Sridhar, Mammo, and Sarraf are paid consultants of EyePoint Pharmaceuticals; however, the statements made are the opinions of Drs. Sridhar, Mammo, and Sarraf for educational purposes only; their statements are not intended as medical advice or the opinion of EyePoint.
    Más Menos
    29 m
  • Global Discussions in GA: Educating Patients and Encouraging Follow-Up

    Global Discussions in GA: Educating Patients and Encouraging Follow-Up
    Nov 25 2025
    How are the world's leading mind on GA management educating patients about GA so they follow-up with their providers? Host Anat Loewenstein, MD, convenes a roundtable with Jordi Monés, MD, PhD; Sobha Sivaprasad, MD; and Giovanni Staurenghi, MD, to review their specific approaches to GA management, patient conversations, and education for patients and caregivers. Plus, are AREDS supplements an option for GA patients?
    Más Menos
    23 m
  • Global Discussions in GA: Referral Patterns and Fellow-Eye Monitoring

    Global Discussions in GA: Referral Patterns and Fellow-Eye Monitoring
    Nov 25 2025
    At what point in their disease do world-renowned retina specialists want to see patients with GA? Host Anat Loewenstein, MD, leads a candid roundtable with Jordi Monés, MD, PhD; Sobha Sivaprasad, MD; and Giovanni Staurenghi, MD, on modern referral patterns, monitoring intervals, and fellow-eye surveillance. The panel explores the utility of OCT and FAF imaging, discusses patient/caregiver education, and the promise of AI tools in caring for GA patients.
    Más Menos
    13 m